Cholangiocarcinoma

123

Pipeline Programs↗

46

Active Trials↗

62

Companies Involved↗

Cholangiocarcinoma is a highly competitive landscape with 123 programs across 62 companies. The most active players are Halozyme Therapeutics, PCI Biotech AS, AnHeart Therapeutics Inc.. 6 therapies are approved with 26 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

30/100

Mech. Concentration

6/100

Completion Rate

63/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Halozyme Therapeutics

3 programs

PCI Biotech AS

1 program

AnHeart Therapeutics Inc.

1 program

EMD Serono Research & Development Institute, Inc.

1 program

Prism Pharmaceuticals

1 program

GSK

1 program

Pipeline

Programs by Phase

Preclinical12

Doxorubicin

Pfizer

S-1

Taiho Oncology, Inc.

Apatinib

LaNova Medicines Zhejiang Co., Ltd.

Adjuvant Chemotherapy

Nizhny Novgorod Regional Clinical Oncology Center

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 114

Afatinib

Boehringer Ingelheim

Bintrafusp Alfa

EMD Serono Research & Development Institute, Inc.

Infigratinib

Helsinn Healthcare SA

Atezolizumab

Roche

Sirolimus

Prism Pharmaceuticals

Phase 265

Erdafitinib

Johnson & Johnson

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Pembrolizumab

Merck & Co.

Toripalimab

Coherus Oncology, Inc.

Phase 326

Futibatinib

Taiho Oncology, Inc.

Lenvatinib

Eisai

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Gemcitabine

Johnson & Johnson

Tegafur

The First Affiliated Hospital with Nanjing Medical University

Approved6

Calcitriol

Alnylam Pharmaceuticals

Ceritinib

Novartis

Leucovorin

Glaxo Dba Glaxosmithkline

Colchicine

Alnylam Pharmaceuticals

Irinotecan

Pfizer

Analysis

Modality Breakdown

81%

Small molecule

116 of 143 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 143 classified programs, each share of the total. Modality classified for 99% of 148 pipeline programs.

Analysis

Trial Status

134

clinical trials

Completed44 · 33%

Recruiting28 · 21%

Terminated20 · 15%

Unknown status16 · 12%

Active, not recruiting10 · 7%

Not yet recruiting7 · 5%

Other9 · 7%

Clinical Trials

Trial Activity

134 trials

Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06439485·25 enrolled

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Recruiting· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 1/2·NCT06501625·52 enrolled

Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06718257·300 enrolled

Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

Recruiting·UUniversity Hospital, Montpellier·Phase 2·NCT03364530·40 enrolled

Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06607276·122 enrolled

HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)

Recruiting·OOslo University Hospital·Phase 2·NCT06313203·39 enrolled

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT06440993·42 enrolled

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT07260175·40 enrolled

Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy

Recruiting·—·Phase 2·NCT06375915·33 enrolled

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Recruiting·TTyra Biosciences, Inc·Phase 1·NCT06160752·40 enrolled

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Recruiting·AAustralasian Gastro-Intestinal Trials Group·Phase 2·NCT06441747·40 enrolled

The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma

Recruiting·MMara Veenstra, MD·Phase 2/3·NCT06355427·81 enrolled

Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma

Recruiting·National Cancer Institute, Naples·Phase 2·NCT06341764·38 enrolled

Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma

Recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT07105852·59 enrolled

HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)

Recruiting·FFudan University·Phase 2·NCT07105748·45 enrolled

Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)